NFL News: Andy Reid's Chiefs sign a key veteran to help Patrick Mahomes, Travis Kelce The Ocean Has Massive Energy Reserves.

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Swiss pharmaceutical giant Roche said Wednesday that it was increasing its capacity to produce diagnostic tests to detect ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...